Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | GAA | P10253 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | CPB1 | P15086 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | DPP4 | P27487 | 5/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9885094 | 1.00 | ALDH1A1 (0.78) | ALDH1A1GAATSHRCPB1EPHX1 | |
| SCHEMBL7286285 | 1.00 | ALDH1A1 (0.78) | ALDH1A1GAATSHRCPB1EPHX1 | |
| SCHEMBL4204190 | 0.90 | ALDH1A1 (0.74) | ALDH1A1GAATSHRCPB1EPHX1 | |
| SCHEMBL13275989 | 0.89 | ALDH1A1 (0.64) | ALDH1A1GAATSHRCPB1EPHX1 | |
| SCHEMBL12525124 | 0.89 | ALDH1A1 (0.64) | ALDH1A1GAATSHRCPB1EPHX1 | |
| SCHEMBL3948461 | 0.89 | ALDH1A1 (0.85) | ALDH1A1GAATSHRCPB1EPHX1 | |
| SCHEMBL3948456 | 0.89 | ALDH1A1 (0.85) | ALDH1A1GAATSHRCPB1EPHX1 | |
| SCHEMBL381922 | 0.89 | ALDH1A1 (0.85) | ALDH1A1GAATSHRCPB1EPHX1 | |
| SCHEMBL2014111 | 0.88 | ALDH1A1 (0.80) | ALDH1A1GAATSHRCPB1EPHX1 | |
| SCHEMBL2014110 | 0.88 | ALDH1A1 (0.80) | ALDH1A1GAATSHRCPB1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2955181-B1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | NISSAN CHEMICAL CORP (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-10385052-B2 | Tricyclic compound and JAK inhibitor | NISSAN CHEMICAL CORPORATION (JP) | 2019-08-20 | — | — | US | disclosed |
| EP-3144309-B1 | TRICYCLIC COMPOUND AND JAK INHIBITOR | NISSAN CHEMICAL CORP (JP) | 2019-08-14 | — | — | EP | disclosed |
| US-20180099966-A1 | TRICYCLIC COMPOUND AND JAK INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-04-12 | — | — | US | disclosed |
| US-9890165-B2 | Tricyclic compound and JAK inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9890165-B2 | Tricyclic compound and JAK inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-9890165-B2 | Tricyclic compound and JAK inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | SYNGENE INTERNATIONAL LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| EP-3144309-A1 | TRICYCLIC COMPOUND AND JAK INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2017-03-22 | — | — | EP | disclosed |
| CN-106459050-A | Tricyclic compounds and JAK inhibitors | 日产化学工业株式会社 | 2017-02-22 | — | — | CN | disclosed |
| US-20170044161-A1 | TRICYCLIC COMPOUND AND JAK INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-02-16 | — | — | US | disclosed |
| US-9475813-B2 | Tricyclic pyrrolopyridine compound, and JAK inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9475813-B2 | Tricyclic pyrrolopyridine compound, and JAK inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9475813-B2 | Tricyclic pyrrolopyridine compound, and JAK inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-10-25 | — | — | US | disclosed |
| US-20150368245-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-20150368245-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
| US-20150368245-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
| EP-2955181-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2015-12-16 | — | — | EP | disclosed |
| EP-2955181-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014123167-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | 日産化学工業株式会社 (JP) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099966-A1 | TRICYCLIC COMPOUND AND JAK INHIBITOR | JAK1, JAK3, JAK2 | ALDH1A1 2772/4885GAA 3463/4885TSHR 1371/4885 |
| US-20150368245-A1 | TRICYCLIC PYRROLOPYRIDINE COMPOUND, AND JAK INHIBITOR | JAK1, JAK2, JAK3 | ALDH1A1 3494/4885GAA 4353/4885TSHR 1237/4885 |
| US-10385052-B2 | Tricyclic compound and JAK inhibitor | JAK1, JAK3, JAK2 | ALDH1A1 2746/4885GAA 3582/4885TSHR 1433/4885 |
| US-20170044161-A1 | TRICYCLIC COMPOUND AND JAK INHIBITOR | JAK1, JAK3, JAK2 | ALDH1A1 2635/4885GAA 3410/4885TSHR 1463/4885 |
| US-20170114029-A1 | TREATMENT OF CHAGAS DISEASE | CXCR4, CBR1, CHRM1 | ALDH1A1 2686/4885GAA 3228/4885TSHR 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.